See more : JGC Holdings Corporation (JGCCY) Income Statement Analysis – Financial Results
Complete financial analysis of Phio Pharmaceuticals Corp. (PHIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phio Pharmaceuticals Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- New Residential Investment Corp. (NRZ-PC) Income Statement Analysis – Financial Results
- Falcon Capital Acquisition Corp. (FCACU) Income Statement Analysis – Financial Results
- Gibui Holdings Ltd (GIBUI.TA) Income Statement Analysis – Financial Results
- DFP Healthcare Acquisitions Corp. (DFPHW) Income Statement Analysis – Financial Results
- Santosh Fine Fab Limited (SANTOSHF.BO) Income Statement Analysis – Financial Results
Phio Pharmaceuticals Corp. (PHIO)
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 138.00K | 15.00K | 19.00K | 34.00K | 71.00K | 399.00K | 97.00K | 0.00 |
| Cost of Revenue | 6.33M | 193.00K | 192.00K | 183.00K | 4.30K | 4.33M | 5.37M | 5.42M | 6.93M | 5.68M | 17.65M | 12.98M | 0.00 |
| Gross Profit | -6.33M | -193.00K | -192.00K | -183.00K | 16.70K | -4.19M | -5.36M | -5.40M | -6.89M | -5.61M | -17.25M | -12.88M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 79.52% | -3,034.78% | -35,700.00% | -28,400.00% | -20,267.65% | -7,900.00% | -4,323.81% | -13,276.29% | 0.00% |
| Research & Development | 6.33M | 7.01M | 8.89M | 4.43M | 4.30M | 4.33M | 5.37M | 5.42M | 6.93M | 5.68M | 17.65M | 10.45M | 6.62M |
| General & Administrative | 4.29M | 4.45M | 4.63M | 4.36M | 4.71M | 3.18M | 4.01M | 3.62M | 3.35M | 3.22M | 3.70M | 2.62M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.29M | 4.45M | 4.63M | 4.36M | 4.71M | 3.18M | 4.01M | 3.62M | 3.35M | 3.22M | 3.70M | 2.62M | 6.15M |
| Other Expenses | -6.13M | -18.00K | 224.00K | -1.00K | 79.00K | 4.00K | 4.70M | 3.11M | 2.44M | 2.21M | 2.63M | 0.00 | 0.00 |
| Operating Expenses | 4.49M | 11.46M | 13.51M | 8.79M | 9.01M | 7.50M | 9.38M | 9.03M | 10.27M | 8.90M | 21.35M | 13.07M | 12.77M |
| Cost & Expenses | 10.82M | 11.46M | 13.51M | 8.79M | 9.01M | 7.50M | 9.38M | 9.03M | 10.27M | 8.90M | 21.35M | 13.07M | 12.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.00K | 30.00K | 0.00 |
| Depreciation & Amortization | 184.00K | 193.00K | 192.00K | 183.00K | 67.00K | 81.00K | 70.00K | 53.00K | 77.00K | 87.00K | 99.00K | 147.00K | 163.00K |
| EBITDA | -10.64M | -11.29M | -13.09M | -8.72M | -8.92M | -7.28M | -14.00M | -8.96M | -10.16M | -8.74M | -20.85M | -12.70M | -15.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,795.24% | -5,336.23% | -31,060.00% | -47,557.89% | -30,102.94% | -12,443.66% | -5,225.56% | -13,353.61% | 0.00% |
| Operating Income | -10.82M | -11.46M | -13.51M | -8.79M | -8.99M | -7.36M | -14.06M | -9.02M | -10.24M | -8.83M | -20.95M | -12.98M | -12.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,795.24% | -5,336.23% | -93,746.67% | -47,447.37% | -30,108.82% | -12,430.99% | -5,250.38% | -13,376.29% | 0.00% |
| Total Other Income/Expenses | -2.00K | -18.00K | 224.00K | -1.00K | 79.00K | 4.00K | -11.00K | 21.00K | 14.00K | 26.00K | 24.00K | 108.00K | 2.55M |
| Income Before Tax | -10.83M | -11.48M | -13.29M | -8.79M | -8.91M | -7.36M | -14.07M | -8.99M | -10.22M | -8.80M | -20.93M | -12.88M | -10.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,419.05% | -5,333.33% | -93,820.00% | -47,336.84% | -30,067.65% | -12,394.37% | -5,244.36% | -13,278.35% | 0.00% |
| Income Tax Expense | 0.00 | -175.00K | -75.00K | -134.30K | -67.00K | 4.00K | -1.62M | -74.00K | -91.00K | -113.00K | 0.00 | -95.00K | -2.55M |
| Net Income | -10.83M | -11.31M | -13.21M | -8.79M | -8.84M | -7.36M | -12.45M | -8.99M | -10.22M | -8.80M | -20.93M | -12.88M | -10.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,100.00% | -5,333.33% | -83,013.33% | -47,336.84% | -30,067.65% | -12,394.37% | -5,244.36% | -13,278.35% | 0.00% |
| EPS | -46.87 | -89.61 | -111.32 | -207.25 | -2.07K | -6.22K | -32.80K | -79.28K | -93.03K | -238.08K | -1.06M | -1.45M | -1.30M |
| EPS Diluted | -46.76 | -89.61 | -111.32 | -207.25 | -2.07K | -6.22K | -32.80K | -79.28K | -93.03K | -238.08K | -1.06M | -1.45M | -1.30M |
| Weighted Avg Shares Out | 231.00K | 126.16K | 118.68K | 42.43K | 4.26K | 1.18K | 379.62 | 113.44 | 109.89 | 36.96 | 19.76 | 8.88 | 7.88 |
| Weighted Avg Shares Out (Dil) | 231.51K | 126.16K | 118.68K | 42.43K | 4.26K | 1.18K | 379.62 | 113.44 | 109.89 | 36.96 | 19.76 | 8.88 | 7.88 |
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use...
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has...
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a...
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology...
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
PH-894: Potent and Specific Silencing of BRD4 in NK Cells Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA...
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 2, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology...
Source: https://incomestatements.info
Category: Stock Reports